Stock listing

NASDAQ:CMND Clearmind Medicine Inc. Stock

Home listing (NASDAQ) of Clearmind Medicine Inc.

Follow Clearmind Medicine Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CMND

$2.63 USD -0.43 (-14.2%)

Close on Nov 20, 2026

Past year -99.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.63 – $3.28 USDNov 20, 2026
Volume
9,837 sharesNov 20, 2026
Market cap
$1.33M USDAt the close on Nov 20, 2026 · price × 507,404 shares outstanding
52-week range
$2.63 – $694.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$102,341 USDMedian day 4,993 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Clearmind Medicine Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CMND · Home$2.63 USD-0.435 (-14.2%)9,837$3.09$3.28$2.63$3.065Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CMND · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.63-0.435-14.2%$3.09$3.28$2.639,837
$3.065-0.385-11.2%$3.45$3.45$3.034,993
$3.45-0.733-17.5%$4.00$4.00$3.2412,554
$4.183-0.347-7.7%$4.24$4.25$4.005,173
$4.53-0.09-1.9%$4.52$4.785$4.353,426
$4.62-0.33-6.7%$4.775$4.811$4.6210,502
$4.95-0.14-2.8%$5.415$5.579$4.935,603
$5.09-0.41-7.5%$5.76$5.76$5.096,941
$5.50-0.084-1.5%$5.70$5.77$5.405,070
$5.584-0.266-4.6%$5.71$5.71$5.4013,405
$5.85-0.07-1.2%$5.925$5.99$5.603,512
$5.920.000.0%$5.992$6.107$5.813,492
$5.92-0.22-3.6%$5.81$6.10$5.434,681
$6.14-0.079-1.3%$6.02$6.14$6.021,827
$6.219+0.369+6.3%$5.83$6.499$5.839,470
$5.85-0.21-3.5%$6.15$6.15$5.854,301
$6.06+0.093+1.6%$6.00$6.10$5.985,022
$5.967-0.154-2.5%$6.095$6.095$5.9485,341
$6.121+0.251+4.3%$5.92$6.20$5.8616,232
$5.87-0.13-2.2%$6.255$6.255$5.878,342
$6.00+0.06+1.0%$6.01$6.04$6.005,297
$5.94-0.18-2.9%$6.253$6.253$5.945,216
$6.12+0.12+2.0%$5.971$6.14$5.916,974
$6.00-0.26-4.2%$6.164$6.362$5.918,271
$6.26-0.16-2.5%$6.33$6.47$6.264,137
$6.42+0.131+2.1%$6.24$6.79$6.245,684
$6.289+0.059+0.9%$6.36$6.47$6.2010,814
$6.23-0.31-4.7%$6.50$6.73$6.2311,000
$6.54-0.04-0.6%$6.52$6.80$6.48116,100
$6.58-0.02-0.3%$6.77$6.94$6.359,100
$6.600.000.0%$6.64$7.16$6.4041,100
$6.60+0.76+13.0%$5.75$6.70$5.54146,400
$5.84-0.16-2.7%$5.89$6.175$5.70135,400
$6.00+0.28+4.9%$5.93$6.54$5.2589,200
$5.72-0.008-0.1%$5.92$5.92$5.6481,522
$5.728-0.712-11.1%$6.00$6.096$5.6723,428
$6.44-0.048-0.7%$6.52$6.72$6.401,559
$6.488+0.184+2.9%$6.256$6.576$6.256538
$6.304-0.12-1.9%$6.40$6.544$6.2641,422
$6.424-0.056-0.9%$6.72$6.72$6.416886
$6.48-0.32-4.7%$6.808$6.808$6.40978
$6.80+0.552+8.8%$6.432$6.80$6.245,839
$6.248-0.08-1.3%$6.24$6.32$6.1761,169
$6.328-0.064-1.0%$6.32$6.40$6.201,883
$6.392-0.472-6.9%$6.80$6.864$6.162,991
$6.864+0.416+6.5%$6.592$8.48$6.50424,967
$6.448-0.464-6.7%$6.728$6.776$6.322,399
$6.912-0.64-8.5%$7.344$7.464$6.6642,613
$7.552-0.184-2.4%$7.52$7.76$7.3362,561
$7.736-0.12-1.5%$8.00$8.48$7.604,433
$7.856-0.624-7.4%$8.00$8.36$7.841,581
$8.48+0.24+2.9%$8.56$8.88$8.005,134
$8.24-1.04-11.2%$9.20$9.20$7.3648,711
$9.28-4.32-31.8%$11.96$12.44$9.28242,381
$13.60-1.20-8.1%$14.48$14.72$13.60922
$14.80+0.16+1.1%$14.80$14.96$14.32694
$14.64-0.88-5.7%$15.44$15.44$14.083,378
$15.52+1.44+10.2%$14.56$16.80$14.4811,170
$14.08-0.40-2.8%$14.56$14.72$13.84384
$14.48+0.72+5.2%$14.80$14.80$14.001,019
$13.76+0.08+0.6%$13.44$13.92$13.28567
$13.68+0.24+1.8%$13.52$14.00$13.20664
$13.44-0.48-3.4%$14.00$14.00$12.881,516
$13.92+0.08+0.6%$13.92$14.68$13.92717
$13.84-1.44-9.4%$15.44$15.44$13.601,709

Splits

4 splits since 2023 · NASDAQ:CMND · every price before a split is adjusted for it

DayRatioWhat
1-for-8Consolidation
1-for-10Consolidation
1-for-40Consolidation
1-for-30Consolidation
Ticker
NASDAQ:CMND
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Clearmind Medicine Inc. news

Clearmind Medicine Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
68 in the last 12 months · 167 in all · newest Nov 19, 2026 · oldest 2022
Decks
4 decks · latest November 2025

Where Clearmind Medicine Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CMND · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CMNDBOATSUnited StatesUSD
gettex:CWYgettexGermanyEUR
Lang & Schwarz:A41YK5Lang & SchwarzGermanyEUR
LS Exchange:A41YK5LS ExchangeGermanyEUR
Frankfurt:CWY0FrankfurtGermanyEUR
Lang & Schwarz:A427B1Lang & SchwarzGermanyEUR
Munich:CWYMunichGermanyUSD
Munich:CWY0MunichGermanyEUR

Valuation

Price/book 0.2× against a median of 0.3×: 3rd lowest of 8 Biotechnology companies shown. Statements: Year to Oct 31, 2025 · balance Jan 31, 2026 · price Nov 20, 2026

Enterprise value
−$9.01M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.29

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Clearmind Medicine Inc. · NASDAQ:CMNDUS$1.33M−US$9.01Mn/an/an/a0.2×n/a0.0×0.29
PRF Technologies Ltd. · NASDAQ:PRFXUS$1.66M−US$9.82Mn/a−249×n/a0.1×n/a0.0×1.93
Jupiter Neurosciences, Inc. · NASDAQ:JUNSUS$1.63MUS$1.33Mn/a16.9×n/an/an/an/a1.88
Kairos Pharma, Ltd. · AMEX:KAPAUS$1.48M−US$1.65Mn/an/an/a0.4×n/a0.0×1.36
BioRestorative Therapies, Inc. · NASDAQ:BRTXUS$1.45M−US$2.11Mn/a−5.9×n/a0.5×n/a0.0×1.81
Nutra Pharma Corp. · OTC:NPHCUS$1.43MUS$13.99Mn/a87.0×n/an/an/an/an/a
Aptevo Therapeutics Inc. · NASDAQ:APVOUS$1.40M−US$2.88Mn/an/an/a0.4×n/a1.0×0.93
Agentix Corp. · OTC:AGTXUS$1.35MUS$1.34Mn/an/an/an/an/an/a-0.73
Artelo Biosciences, Inc. · NASDAQ:ARTLUS$1.30MUS$1.34Mn/an/an/a0.2×n/a0.0×1.36
International Stem Cell Corporation · OTC:ISCOUS$1.28M−US$18.76M0.1×−2.0×n/a0.1×222.6%0.0×-0.52
SureNano Science Ltd · CSE:SUREUS$1.17MUS$672,321n/an/an/a0.3×n/a0.0×0.25
Median of the othersUS$1.42M−US$488,4960.1×−2.0×0.3×222.6%0.0×1.36

Team and board

Officers

OfficerRole
Adi Zuloff-ShaniCEO
Alan RootenbergChief Financial Officer
Gadi LevinVP Finance
Mark HadenVP Business Development
Adi VaronController
Mary-Elizabeth GiffordChief of Global Impact
Mylene TouboulAccounting Manager

Board

DirectorRole
Amitay WeissChairman of the Board
Asaf ItzhaikDirector
Hila Kiron-RevachDirector
Oz AdlerDirector
Yehonatan ShacharDirector

Events

QuarterResultsShare move
Quarter to Jul 31, 2026Sep 10, 2026−8.8%
Quarter to Apr 30, 2026Jun 15, 2026−6.0%
Q4 2025Jan 20, 2026+2.4%
Q3 2025Sep 11, 2025−0.4%
Q2 2025Jun 12, 2025−3.5%
Q1 2025Mar 13, 2025+0.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck24 slidesNovember 2025
Investor Presentation (July 2025)Investor deck24 slidesJul 29, 2025
Investor Presentation (October 2024)Investor deck19 slidesOctober 2024
Investor Presentation (August 2024)Investor deck13 slidesAug 20, 2024

Open Decks

Financings

RaiseDate
Convertible promissory notes
Tranche closed: US$500,000 raised · Aegis Capital Corp.
Dealers: Aegis Capital Corp.
Use of proceeds: Working capital, general corporate purposes and potential acquisitions to support exploration of strategic opportunities
Sep 19, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$6.50 a share on Nov 14, 2022.

Price
US$6.50 a share
Shares offered
1,153,847 common shares
Offering size
US$7.5 million
Underwriters' option
Up to 173,077 more shares
Listing
CMND on the Nasdaq Capital Market
Underwriter
Aegis Capital Corp.
Shares delivered
On or about Nov 17, 2022

Steps

StepWhen
Draft sent to the SEC in confidenceDec 27, 2021
Filed publiclyJun 29, 2022
Amended 9 timesNewest Nov 14, 2022
Shares registered with an exchangeNov 9, 2022
Declared effective by the SECNov 14, 2022
Final prospectus, with the priceNov 16, 2022

Filings

FilingFiled
424B4 · ProspectusNov 16, 2022
CERT · Exchange's certificate of listingNov 15, 2022
EFFECT · Notice that a registration is effectiveNov 14, 2022
F-1/A · Registration statement, amendedNov 14, 2022
CORRESP · Letter to the SECNov 9, 2022
CORRESP · Letter to the SECNov 9, 2022
8-A12B · Registration of shares for listing on an exchangeNov 9, 2022
CORRESP · Letter to the SECNov 9, 2022
F-1/A · Registration statement, amendedNov 9, 2022
UPLOAD · Letter from the SECNov 8, 2022
All 43 filings
FilingFiled
F-1/A · Registration statement, amendedNov 4, 2022
CORRESP · Letter to the SECNov 3, 2022
UPLOAD · Letter from the SECNov 2, 2022
F-1/A · Registration statement, amendedNov 2, 2022
CORRESP · Letter to the SECNov 1, 2022
UPLOAD · Letter from the SECOct 31, 2022
F-1/A · Registration statement, amendedOct 26, 2022
CORRESP · Letter to the SECOct 26, 2022
UPLOAD · Letter from the SECOct 25, 2022
FWP · Free writing prospectusOct 24, 2022
CORRESP · Letter to the SECOct 20, 2022
F-1/A · Registration statement, amendedOct 20, 2022
UPLOAD · Letter from the SECOct 13, 2022
CORRESP · Letter to the SECOct 6, 2022
F-1/A · Registration statement, amendedOct 6, 2022
UPLOAD · Letter from the SECSep 29, 2022
F-1/A · Registration statement, amendedSep 21, 2022
CORRESP · Letter to the SECSep 20, 2022
UPLOAD · Letter from the SECSep 1, 2022
CORRESP · Letter to the SECAug 18, 2022
F-1/A · Registration statement, amendedAug 18, 2022
UPLOAD · Letter from the SECJul 7, 2022
CORRESP · Letter to the SECJun 29, 2022
CORRESP · Letter to the SECJun 29, 2022
F-1 · Registration statementJun 29, 2022
UPLOAD · Letter from the SECJun 21, 2022
DRSLTR · Letter to the SEC with a draftJun 10, 2022
DRS/A · Draft registration statement, amendedJun 10, 2022
UPLOAD · Letter from the SECMay 24, 2022
DRSLTR · Letter to the SEC with a draftApr 27, 2022
DRS/A · Draft registration statement, amendedApr 27, 2022
UPLOAD · Letter from the SECJan 24, 2022
DRS · Draft registration statementDec 27, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Nov 16, 2022

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Research and development2.06M1.38M1.54M3.08M473.7K
Selling, general and administrative4.36M4.76M3.17M2.22M
Depreciation and amortization38.4K1.06K11.2K7.57K1.88K
Interest expense3.86K5.39K
Income before tax-3.79M-4.88M-8.60M-6.87M-2.73M
Income tax70.4K378.0K17.4K29.9K
Net income-3.86M-5.25M-8.62M-6.89M-2.73M
Earnings per share, basic-30.35-67.80-1,703.04-159.11-88.16
Earnings per share, diluted-30.35-67.80-1,703.04-159.11-88.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents3.92M6.57M5.43M128.8K3.37M
Short-term investments1.66M289.4K86.1K
Receivables50.9K
Current assets5.95M7.09M5.79M434.7K
Property, plant and equipment1.73K12.9K
Total assets6.08M7.26M5.95M826.4K
Accounts payable526.1K617.0K
Current liabilities4.89M4.13M4.97M
Total liabilities4.89M4.15M4.97M1.93M
Shareholders' equity1.19M3.11M983.5K-1.11M3.52M
Shares outstanding44.0K1.25M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-4.73M-4.86M-6.30M-3.72M-2.08M
Capital spending-5.56K-17.0K
Free cash flow-3.73M-2.09M
Cash from investing-542.0K-238.1K-26.2K-5.56K-184.0K
Cash from financing2.62M6.25M11.7M511.7K5.39M
Change in cash-2.65M1.15M5.30M-3.24M3.13M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
6-K · Report of a foreign issuerNov 10, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerOct 27, 2026Current reportSEC
6-K · Report of a foreign issuerOct 16, 2026Current reportSEC
6-K · Report of a foreign issuerOct 13, 2026Current reportSEC
6-K · Report of a foreign issuerOct 8, 2026Current reportSEC
6-K · Report of a foreign issuerOct 7, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerSep 30, 2026Current reportSEC
6-K · Report of a foreign issuerSep 23, 2026Current reportSEC
6-K · Report of a foreign issuerSep 17, 2026Current reportSEC
6-K · Report of a foreign issuerSep 14, 2026Current reportSEC
6-K · Report of a foreign issuerSep 10, 2026Current reportSEC
6-K · Report of a foreign issuerSep 8, 2026Current reportSEC
6-K · Report of a foreign issuerSep 4, 2026Current reportSEC
6-K · Report of a foreign issuerSep 2, 2026Current reportSEC
6-K · Report of a foreign issuerSep 1, 2026Current reportSEC
6-K · Report of a foreign issuerAug 24, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerAug 11, 2026Current reportSEC
6-K · Report of a foreign issuerAug 6, 2026Current reportSEC
6-K · Report of a foreign issuerAug 3, 2026Current reportSEC
6-K · Report of a foreign issuerJul 30, 2026Current reportSEC
6-K · Report of a foreign issuerJul 20, 2026Current reportSEC
6-K · Report of a foreign issuerJul 17, 2026Current reportSEC
6-K · Report of a foreign issuerJul 16, 2026Current reportSEC
6-K · Report of a foreign issuerJul 13, 2026Current reportSEC
6-K · Report of a foreign issuerJul 10, 2026Current reportSEC
6-K · Report of a foreign issuerJul 7, 2026Current reportSEC
6-K · Report of a foreign issuerJun 29, 2026Current reportSEC
6-K · Report of a foreign issuerJun 22, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 18, 2026Current reportSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 16, 2026Current reportSEC
POS AM · Amendment to an effective registrationJun 15, 2026Offer documentSEC
6-K · Report of a foreign issuerJun 15, 2026Current reportSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 12, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 12, 2026Current reportSEC
6-K · Report of a foreign issuerJun 1, 2026Current reportSEC
6-K · Report of a foreign issuerMay 29, 2026Current reportSEC
6-K · Report of a foreign issuerMay 26, 2026Current reportSEC
6-K · Report of a foreign issuerMay 19, 2026Current reportSEC
6-K · Report of a foreign issuerMay 19, 2026Current reportSEC
6-K · Report of a foreign issuerMay 18, 2026Current reportSEC
6-K · Report of a foreign issuerMay 18, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerMay 12, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMay 8, 2026Other filingsSEC
CORRESP · Letter to the SECMay 6, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 6, 2026Other filingsSEC
6-K · Report of a foreign issuerMay 5, 2026Current reportSEC
F-3 · Registration statementApr 30, 2026Offer documentSEC
6-K · Report of a foreign issuerApr 30, 2026Current reportSEC
6-K · Report of a foreign issuerApr 27, 2026Current reportSEC
6-K · Report of a foreign issuerApr 21, 2026Current reportSEC
6-K · Report of a foreign issuerApr 20, 2026Current reportSEC
6-K · Report of a foreign issuerApr 20, 2026Current reportSEC
6-K · Report of a foreign issuerApr 15, 2026Current reportSEC
6-K · Report of a foreign issuerApr 15, 2026Current reportSEC
6-K · Report of a foreign issuerApr 14, 2026Current reportSEC
6-K · Report of a foreign issuerApr 14, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMar 31, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 31, 2026Other filingsSEC
6-K · Report of a foreign issuerMar 30, 2026Current reportSEC
6-K · Report of a foreign issuerMar 27, 2026Current reportSEC
POS AM · Amendment to an effective registrationMar 25, 2026Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2026Offer documentSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
6-K · Report of a foreign issuerMar 17, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 16, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerMar 13, 2026Current reportSEC
6-K · Report of a foreign issuerMar 12, 2026Current reportSEC
6-K · Report of a foreign issuerMar 11, 2026Current reportSEC
6-K · Report of a foreign issuerMar 10, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 9, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerMar 4, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 27, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 25, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 25, 2026Other filingsSEC
F-3 · Registration statementFeb 17, 2026Offer documentSEC
6-K · Report of a foreign issuerFeb 17, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 11, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 9, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 6, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 4, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
POS AM · Amendment to an effective registrationJan 27, 2026Offer documentSEC
POS AM · Amendment to an effective registrationJan 27, 2026Offer documentSEC
POS AM · Amendment to an effective registrationJan 27, 2026Offer documentSEC
20-F · Annual reportJan 20, 2026Annual reportSEC
6-K · Report of a foreign issuerJan 14, 2026Current reportSEC
6-K · Report of a foreign issuerDec 31, 2025Current reportSEC
6-K · Report of a foreign issuerDec 29, 2025Current reportSEC
6-K · Report of a foreign issuerDec 16, 2025Current reportSEC
6-K · Report of a foreign issuerDec 12, 2025Current reportSEC
6-K · Report of a foreign issuerDec 12, 2025Current reportSEC
6-K · Report of a foreign issuerDec 10, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 10, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveDec 10, 2025Other filingsSEC
CORRESP · Letter to the SECDec 8, 2025Other filingsSEC
6-K · Report of a foreign issuerDec 5, 2025Current reportSEC
F-1/A · Registration statement, amendedDec 5, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 5, 2025Current reportSEC
6-K · Report of a foreign issuerDec 3, 2025Current reportSEC
424B5 · ProspectusDec 3, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 2, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 1, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 1, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 28, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 28, 2025Current reportSEC
F-1 · Registration statementNov 26, 2025Offer documentSEC
6-K · Report of a foreign issuerNov 26, 2025Current reportSEC
424B5 · ProspectusNov 26, 2025Offer documentSEC
6-K · Report of a foreign issuerNov 25, 2025Current reportSEC
6-K · Report of a foreign issuerNov 24, 2025Current reportSEC
6-K · Report of a foreign issuerNov 20, 2025Current reportSEC
6-K · Report of a foreign issuerNov 19, 2025Current reportSEC
424B5 · ProspectusNov 19, 2025Offer documentSEC
6-K · Report of a foreign issuerNov 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 18, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 17, 2025Current reportSEC
6-K · Report of a foreign issuerNov 17, 2025Current reportSEC
424B5 · ProspectusNov 17, 2025Offer documentSEC
6-K · Report of a foreign issuerNov 13, 2025Current reportSEC
6-K · Report of a foreign issuerNov 13, 2025Current reportSEC
424B5 · ProspectusNov 13, 2025Offer documentSEC
6-K · Report of a foreign issuerNov 12, 2025Current reportSEC
6-K · Report of a foreign issuerNov 6, 2025Current reportSEC
6-K · Report of a foreign issuerNov 5, 2025Current reportSEC
6-K · Report of a foreign issuerOct 31, 2025Current reportSEC
6-K · Report of a foreign issuerOct 30, 2025Current reportSEC
6-K · Report of a foreign issuerOct 27, 2025Current reportSEC
6-K · Report of a foreign issuerOct 21, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveOct 1, 2025Other filingsSEC
CORRESP · Letter to the SECSep 30, 2025Other filingsSEC
6-K · Report of a foreign issuerSep 25, 2025Current reportSEC
UPLOAD · Letter from the SECSep 24, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 22, 2025Other filingsSEC
F-1 · Registration statementSep 19, 2025Offer documentSEC
6-K · Report of a foreign issuerSep 19, 2025Current reportSEC
6-K · Report of a foreign issuerSep 17, 2025Current reportSEC
POS AM · Amendment to an effective registrationSep 15, 2025Offer documentSEC
6-K · Report of a foreign issuerSep 11, 2025Current reportSEC
6-K · Report of a foreign issuerAug 7, 2025Current reportSEC
6-K · Report of a foreign issuerAug 5, 2025Current reportSEC
6-K · Report of a foreign issuerJul 30, 2025Current reportSEC
6-K · Report of a foreign issuerJul 29, 2025Current reportSEC
6-K · Report of a foreign issuerJul 15, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 3, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJul 3, 2025Current reportSEC
6-K · Report of a foreign issuerJun 30, 2025Current reportSEC
6-K · Report of a foreign issuerJun 27, 2025Current reportSEC
6-K · Report of a foreign issuerJun 23, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJun 20, 2025Other filingsSEC
POS AM · Amendment to an effective registrationJun 12, 2025Offer documentSEC
6-K · Report of a foreign issuerJun 12, 2025Current reportSEC
6-K · Report of a foreign issuerJun 12, 2025Current reportSEC
6-K · Report of a foreign issuerJun 5, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
6-K · Report of a foreign issuerApr 25, 2025Current reportSEC
6-K · Report of a foreign issuerApr 23, 2025Current reportSEC
6-K · Report of a foreign issuerApr 17, 2025Current reportSEC
6-K · Report of a foreign issuerApr 10, 2025Current reportSEC
6-K · Report of a foreign issuerApr 8, 2025Current reportSEC
6-K · Report of a foreign issuerApr 1, 2025Current reportSEC
6-K · Report of a foreign issuerMar 24, 2025Current reportSEC
6-K · Report of a foreign issuerMar 19, 2025Current reportSEC
6-K · Report of a foreign issuerMar 18, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveMar 18, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMar 13, 2025Offer documentSEC
6-K · Report of a foreign issuerMar 13, 2025Current reportSEC
6-K · Report of a foreign issuerMar 10, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 19, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 4, 2025Current reportSEC
POS AM · Amendment to an effective registrationJan 22, 2025Offer documentSEC
20-F · Annual reportJan 22, 2025Annual reportSEC
6-K · Report of a foreign issuerJan 7, 2025Current reportSEC
6-K · Report of a foreign issuerJan 6, 2025Current reportSEC
6-K · Report of a foreign issuerJan 2, 2025Current reportSEC
6-K · Report of a foreign issuerDec 26, 2024Current reportSEC
S-8 · Registration statement for employee plansDec 9, 2024Offer documentSEC
6-K · Report of a foreign issuerDec 6, 2024Current reportSEC
6-K · Report of a foreign issuerNov 20, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerOct 10, 2024Current reportSEC

This page holds 200 of 376 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Clearmind Medicine Inc.’s releases · as of Sep 19, 2025

Common shares
507,404
Fully diluted
507,404

Fully diluted

LineShares
Common shares507,404

Share count over time

CountShares
Nov 22, 2026507,404
May 19, 2026

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Jane Street31,7246.3%US$25,541Sep 30, 2026
Citadel16,3473.2%US$13,161Sep 30, 2026
XTX Topco Ltd11,2772.2%US$9,079Sep 30, 2026
UBS5,6261.1%US$4,529Sep 30, 2026
AdvisorShares Investments LLC1,4360.28%US$1,156Sep 30, 2026
JPMorgan2<0.01%US$2Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%US$1Sep 30, 2026
RBC1<0.01%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
AdvisorShares Psychedelics ETF1,1690.23%US$2,572Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Hrt Financial LP
10% owner
Sale22,139USD 3.31US$73,280Jun 16, 2026
Hrt Financial LP
10% owner
Sale3,183USD 3.32US$10,568Jun 15, 2026
Hrt Financial LP
10% owner
Sale2,102USD 3.36US$7,063Jun 12, 2026
Hrt Financial LP
10% owner
Sale225,191Jun 11, 2026
Hrt Financial LP
10% owner
Buy2,159,052Jun 10, 2026

Big stakes

StakeStakeSharesDateFiling
Iroquois Capital Management, LLC9.99%335KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Amitay Weiss
Other companies: Maris-Tech Ltd. (Director · Since at least Mar 18, 2026); Nexera Technologies Ltd (Director · Since at least Mar 18, 2026); ParaZero Technologies Ltd. (Director · Since at least Mar 18, 2026); SciSparc Ltd. (Chairman · Since at least Oct 23, 2025); Quantum X Labs Inc. (Director · Since at least Sep 19, 2022); Nexentis Technologies Inc. (Director · Since at least Aug 26, 2020)
Chairman of the Board · Since at least Nov 5, 2026
Gadi Levin
Other companies: BriaCell Therapeutics Corp (Chief Financial Officer & Corporate Secretary · Since at least Aug 1, 2022); Sativus Tech Corp. (CEO · Dec 15, 2021 – Dec 15, 2021 · Past); Quantum X Labs Inc. (Chief Financial Officer · Apr 18, 2017 – Apr 18, 2017 · Past)
VP Finance · Since at least Nov 4, 2026
Oz Adler
Other companies: SciSparc Ltd. (Chief Executive Officer and Chief Financial Officer · Since at least Aug 19, 2026); Polyrizon Ltd. (Director · Since at least Mar 31, 2026)
Director · Since at least Mar 19, 2025
Adi Zuloff-Shani
Other companies: SciSparc Ltd. (Chief Technology Officer · Since at least Mar 18, 2026)
CEO · Since at least Oct 27, 2026
Adi VaronController · Since at least Nov 4, 2026
Alan RootenbergChief Financial Officer · Since at least Nov 5, 2026
Asaf ItzhaikDirector · Since at least Nov 5, 2026
Hila Kiron-RevachDirector · Since at least Nov 5, 2026
Mark HadenVP Business Development · Since at least May 20, 2025
Mary-Elizabeth GiffordChief of Global Impact · Since at least Oct 7, 2026
All 12 people
PersonSeat
Mylene TouboulAccounting Manager · Since at least Nov 4, 2026
Yehonatan ShacharDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Clearmind Medicine Inc.